Plasma | Brain | Brain/Plasma Ratio | Testes | Testes/Plasma Ratio | |
---|---|---|---|---|---|
mdr1a(−/−) mice | |||||
Vehicle | 89 ± 15 | 184 ± 20*** | 2.3 ± 0.24** | 194 ± 34** | 2.1 ± 0.35*** |
Valspodar (50 mg/kg) | 1730 ± 266*** | 666 ± 174** | 0.38 ± 0.08*** | 329 ± 51*** | 0.19 ± 0.01*** |
LY-335979 (50 mg/kg) | 161 ± 24** | 318 ± 52*** | 1.9 ± 0.12*** | 207 ± 46** | 1.3 ± 0.13 |
mdr1a(+/+) mice | |||||
LY-335979 | |||||
Vehicle control | 84 ± 4.9 | 6.6 ± 1.7 | 0.08 ± 0.02 | 47 ± 3.7 | 0.48 ± 0.07 |
1 mg/kg | 74 ± 14 | 9.4 ± 1.7 | 0.11 ± 0.04 | 56 ± 1.7 | 0.81 ± 0.13* |
4 mg/kg | 72 ± 4.8 | 24 ± 4.5*** | 0.33 ± 0.04*** | 95 ± 18* | 1.4 ± 0.33** |
12.5 mg/kg | 71 ± 11 | 60 ± 5.4*** | 0.89 ± 0.16*** | 108 ± 27* | 1.6 ± 0.44* |
25 mg/kg | 89 ± 8.1 | 89 ± 17*** | 1.1 ± 0.28** | 168 ± 61* | 2.0 ± 0.48** |
50 mg/kg | 171 ± 12*** | 243 ± 19*** | 1.4 ± 0.08*** | 187 ± 17*** | 1.2 ± 0.19** |
Valspodar | |||||
1 mg/kg | 92 ± 2.8 | 5.9 ± 2.6 | 0.07 ± 0.03 | 49 ± 5.6 | 0.53 ± 0.05 |
4 mg/kg | 169 ± 22* | 46 ± 21 | 0.25 ± 0.08 | 156 ± 26* | 0.78 ± 0.16 |
12.5 mg/kg | 405 ± 57*** | 398 ± 118* | 0.92 ± 0.15*** | 309 ± 86* | 0.74 ± 0.14 |
25 mg/kg | 872 ± 121*** | 546 ± 145** | 0.55 ± 0.13** | 274 ± 40*** | 0.28 ± 0.04 |
50 mg/kg | 1774 ± 263*** | 652 ± 78*** | 0.38 ± 0.04** | 406 ± 48*** | 0.25 ± 0.02 |
Cyclosporine | |||||
Vehicle control | 103 ± 13 | 9.2 ± 1.2 | 0.10 ± 0.03 | 66 ± 12 | 0.42 ± 0.04 |
1 mg/kg | 120 ± 6.0 | 11 ± 2.4 | 0.10 ± 0.02 | 61 ± 7.0 | 0.51 ± 0.04 |
4 mg/kg | 322 ± 14*** | 45 ± 20* | 0.13 ± 0.06 | 128 ± 10*** | 0.40 ± 0.05 |
12.5 mg/kg | 698 ± 189** | 89 ± 19** | 0.18 ± 0.08 | 195 ± 54* | 0.30 ± 0.07 |
25 mg/kg | 659 ± 57*** | 190 ± 43*** | 0.30 ± 0.08* | 294 ± 50*** | 0.44 ± 0.04 |
50 mg/kg | 954 ± 132*** | 242 ± 46*** | 0.27 ± 0.07* | 245 ± 55** | 0.25 ± 0.07 |
Vehicle control | 99 ± 6.7 | 9.4 ± 3.0 | 0.10 ± 0.02 | 41 ± 6.8 | 0.38 ± 0.06 |
Quinidine (50 mg/kg) | 92 ± 2.5 | 5.1 ± 1.5 | 0.06 ± 0.01 | 47 ± 7.3 | 0.54 ± 0.06 |
Verapamil (12.5 mg) | 91 ± 6.1 | 8.4 ± 2.1 | 0.09 ± 0.02 | 39 ± 3.0 | 0.44 ± 0.06 |
Ketoconazole (50 mg/kg) | 292 ± 68* | 57 ± 14** | 0.20 ± 0.02* | 87 ± 16* | 0.30 ± 0.04 |
Vehicle control | 98 ± 12 | 5.1 ± 1.9 | 0.06 ± 0.01 | 31 ± 5.8 | 0.29 ± 0.02 |
Ritonavir (25 mg/kg) | 618 ± 112*** | 22 ± 3.8** | 0.08 ± 0.05 | 59 ± 3.4 | 0.31 ± 0.14 |
Nelfinavir (50 mg/kg) | 124 ± 11 | 7.9 ± 1.5 | 0.06 ± 0.02 | 47 ± 6.6 | 0.39 ± 0.07 |
Saquinavir (50 mg/kg) | 117 ± 14 | 6.9 ± 1.9 | 0.06 ± 0.01 | 48 ± 11 | 0.43 ± 0.13 |
Indinavir (50 mg/kg) | 100 ± 6.2 | 7.5 ± 0.9 | 0.08 ± 0.01 | 37 ± 8.1 | 0.39 ± 0.05 |
Mice were treated with varying doses of LY-335979 or other known P-gp inhibitors (50 mg/kg, unless noted otherwise) in two divided doses, given 30 min before and simultaneously with [14C]nelfinavir. Data are shown as mean ± S.E. Statistical difference in radioactivity between the two groups of mice (3–5 per group), relative to vehicle control in each group, was assessed using a two-sided Student's t test, with P < .05 as the limit of significance (* P < .05,** P < .01, *** P < .001).